Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-ranging study of MenACWY-TT formulations in young children
2005-001288-73Phase 2Completed
- Sponsor
- GSK
- Start
- May 2005
- Modality
- Vaccines & Immunotherapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of meningococcal group A, C, W, and Y tetanus toxoid conjugate vaccine, Meningococcal group C polysaccharide conjugate vaccine and meningococcal ACYW135 vaccine in meningococcal disease (10 arms), sponsored by GSK. Primary endpoint: Immunogenicity one month after first vaccine dose. Started May 2005; status: completed.
02
Drugs
meningococcal group A, C, W, and Y tetanus toxoid conjugate vaccineMeningococcal group C polysaccharide conjugate vaccinemeningococcal ACYW135 vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2005-001288-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001288-73.